FDA to hold public meeting on patient-focused drug development for chronic pain

May 07, 2018
The U.S. Food and Drug Administration is hosting a public meeting on Patient-Focused Drug Development for Chronic Pain on July 9, from 10 a.m. to 4 p.m. at FDA White Oak Campus in Silver Spring, Md. The FDA is interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. 

FDA is particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs, antidepressants; other medications; and non-pharmacologic interventions or therapies.

To register for this meeting, visit chronicpain-pfdd.eventbrite.com. Early registration is recommended.

If you are attending the meeting in person and are interested in providing comments as part of the initial panel discussion on July 9, indicate so during the registration process. Potential panelists must send a brief summary of responses to the discussion questions below by June 25 to PatientFocused@fda.hhs.gov. Panelists will be confirmed prior to the meeting. Sign-up for Open Public Comment will occur on-site during the day of the meeting.

MS Focus Lending Library


Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more

Study uncovers potential risks of common MS treatment


Study finds an increased risk of events such as stroke, migraine, and depression, and abnormalities in the blood with taking beta interferon for MS.
Learn more

Study: Immunotherapy may provide neuroprotection in MS

October 17, 2018

Researchers could be in a position to achieve neuroprotection without shutting down protective immune responses or blood clotting.
Learn more